<DOC>
	<DOCNO>NCT00022256</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs motexafin gadolinium may make tumor cell sensitive radiation therapy . PURPOSE : Phase II trial study effectiveness motexafin gadolinium plus radiation therapy brain treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Motexafin Gadolinium Plus Radiation Therapy Brain Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety motexafin gadolinium cranial irradiation , term dose-limiting toxicity clinically significant adverse event , patient newly diagnose glioblastoma multiforme . II . Evaluate pharmacokinetics regimen patient . III . Determine survival patient treat regimen . IV . Assess activity daily live neurological status patient treat regimen . OUTLINE : This multicenter study . Patients receive motexafin gadolinium IV 30 minute day 1-5 week 1 2 , day 1 , 3 , 5 week 3-6 . Patients undergo cranial irradiation day 1-5 week 1-6 . Treatment continue absence disease progression unacceptable toxicity . Patients undergo neurological examination activity daily live questionnaire baseline , week 10 , follow-up visit . Patients follow week 10 16 every 2 month thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( GBM ) Grade IV astrocytoma Located supratentorially At least 2 week 4 week since prior surgery GBM No recurrent disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 3.0 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2.0 mg/dL Other : HIV negative No history porphyria No glucose6phosphate dehydrogenase deficiency No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior antineoplastic agent GBM No concurrent chemotherapy 2 week study No concurrent antineoplastic investigational agent Endocrine therapy : Prior concurrent corticosteroid allow Radiotherapy : No prior radiotherapy brain Surgery : See Disease Characteristics Other : Concurrent anticonvulsant allow Other concurrent cancer therapy allow medically necessary</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>